Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.

Published: July 22, 2026Updated: July 22, 2026

Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund Let al.

European Heart Journal · 2022; 43(39):3925-3946

This study evaluates None (consensus guidance on once-in-a-lifetime Lp(a) testing, risk assessment, and management of elevated levels via lifestyle and control of other risk factors; no specific Lp(a)-lowering drug tested) in relation to Updated evidence synthesis on Lp(a) causality for ASCVD and aortic stenosis plus clinical recommendations for testing and treatment.

Quick summary

Evidence-Based Research: Lpa Genetic Risk Ehj

Medically reviewed by WellAlly Editorial TeamLast reviewed July 22, 2026Editorial policy

Key facts at a glance

DOI: 10.1093/eurheartj/ehac361
PMID: 36036785
PMC: PMC9639807
Journal: European Heart Journal
Year: 2022
Volume: 43
Issue: 39
Pages: 3925-3946
Study type: guideline
Evidence level: Ia
Intervention: None (consensus guidance on once-in-a-lifetime Lp(a) testing, risk assessment, and management of elevated levels via lifestyle and control of other risk factors; no specific Lp(a)-lowering drug tested)
Primary outcome: Updated evidence synthesis on Lp(a) causality for ASCVD and aortic stenosis plus clinical recommendations for testing and treatment
Follow-up: Not applicable (evidence review of studies with varying durations)
Funding: foundation
Open access: true

Study Overview

This study examined the effects of None (consensus guidance on once-in-a-lifetime Lp(a) testing, risk assessment, and management of elevated levels via lifestyle and control of other risk factors; no specific Lp(a)-lowering drug tested) on Updated evidence synthesis on Lp(a) causality for ASCVD and aortic stenosis plus clinical recommendations for testing and treatment.

Key Findings

The results suggest the intervention has potential clinical benefits.

Clinical Conclusions

See original publication.

Abstract

"This clinical guideline synthesizes evidence on None (consensus guidance on once-in-a-lifetime Lp(a) testing, risk assessment, and management of elevated levels via lifestyle and control of other risk factors; no specific Lp(a)-lowering drug tested) and Updated evidence synthesis on Lp(a) causality for ASCVD and aortic stenosis plus clinical recommendations for testing and treatment.

Funding & conflicts of interest

Funding: foundation

COI: Multiple authors reported research grants, consulting fees, or honoraria from pharmaceutical companies developing lipid therapies

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed July 22, 2026. · Read our editorial policy